TickerFacts.

Rapport Therapeutics, Inc. (RAPP): R&D Expense

Annual figures by period end, from SEC filings.

$94.79M
Year ended 2025-12-31
$136.67M
Trailing 12 months to 2026-06-30
2023-12-31: $28.00M2024-12-31: $60.94M2025-12-31: $94.79M$94.79M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$94.79M+55.6%2026-03-10, From 2025-01-01
2024-12-31$60.94M+117.6%2026-03-10, From 2024-01-01
2023-12-31$28.00Mn/a2025-03-11, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Rapport Therapeutics, Inc. (RAPP)2025-12-31$94.79M+55.6%
Rigel Pharmaceuticals Inc (RIGL)2025-12-31$33.30M+42.4%
Ardelyx, Inc. (ARDX)2025-12-31$71.53M+36.7%
Syndax Pharmaceuticals Inc (SNDX)2025-12-31$258.78M+7.1%
Dianthus Therapeutics, Inc. (DNTH)2025-12-31$145.64M+75.2%
Olema Pharmaceuticals, Inc. (OLMA)2025-12-31$157.70M+26.6%
Vanda Pharmaceuticals Inc. (VNDA)2025-12-31$109.27M+46.8%
Oruka Therapeutics, Inc. (ORKA)2025-12-31$100.64Mn/a
Theravance Biopharma, Inc. (TBPH)2025-12-31$37.41M-0.6%

Compare RAPP, RIGL, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗